Anavex Life Sciences Corp. held its Annual Meeting of Stockholders on June 10, 2025. Stockholders approved the election of Christopher Missling, PhD, Jiong Ma, PhD, Claus van der Velden, PhD, Athanasios Skarpelos, Steffen Thomas, PhD, and Peter Donhauser, D.O. as directors. An amendment to the company's 2022 Omnibus Incentive Plan, which includes increasing the number of shares authorized for issuance by 4,000,000 and establishing a minimum vesting period of one year for all awards, was also approved. Additionally, stockholders approved the prohibition of liberal share recycling practices.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。